摘要
目的探讨小儿喘息性支气管炎采用孟鲁司特钠治疗的临床效果。方法 60例小儿喘息性支气管炎患儿,按照随机数字法分为对照组和研究组,各30例。对照组患儿采用常规治疗,研究组患儿采用孟鲁司特钠治疗。比较两组患儿临床疗效、咳嗽消失时间、哮鸣音消失时间、气喘消失时间、住院时间以及白细胞介素-12(IL-12)、白细胞介素-10(IL-10)、嗜酸粒细胞阳离子蛋白(ECP)、外周血白三烯E4(LTE4)水平。结果研究组患儿总有效率为96.67%,显著高于对照组的80.00%,差异具有统计学意义(P<0.05)。研究组咳嗽消失时间、哮鸣音消失时间、气喘消失时间及住院时间均短于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患儿IL-10、ECP及LTE4水平均显著降低,IL-12水平均显著升高,且研究组较对照组改善显著,差异具有统计学意义(P<0.05)。两组患儿均未出现呕吐、恶心、心悸、头痛、过敏等不良反应。结论在小儿喘息性支气管炎患儿治疗中选择孟鲁司特钠治疗可显著改善患儿的气道高反应性,具有确切疗效,值得在临床上推广使用。
Objective To investigate the clinical effect of montelukast sodium in the treatment of pediatric asthmatic bronchitis. Methods A total of 60 children with asthmatic bronchitis were divided by random number method into control group and research group, with 30 cases in each group. The control group was treated with conventional therapy, and the research group was treated with montelukast sodium. Comparison were made on clinical efficacy, cough disappearance time, wheeze disappeared time, asthma disappeared time, hospitalization time, interleukin-12（IL-12）, interleukin-10（IL-10）, eosinophil cationic protein（ECP）, and peripheral blood leukotriene E4（LTE4） levels between two groups. Results The research group had obviously higher total effective rate as 96.67% than 80.00% in the control group, and the difference was statistically significant（P〈0.05）. The research group had shorter cough disappearance time, wheeze disappeared time, asthma disappeared time and hospitalization time than the control group, and their difference was statistically significant（P〈0.05）. After treatment, both groups had significantly lower IL-10, ECP and LTE4 levels, and higher IL-12 level. The research group had better improvement than the control group. Their difference was statistically significant（P〈0.05）. There were no vomiting, nausea, palpitation, headache, allergy and other adverse reactions in the two groups. Conclusion In the treatment of children with asthmatic bronchitis, montelukast sodium treatment can significantly improve the children＇s airway hyperresponsiveness with the exact efficacy, and it is worthy of clinical promotion and use.
作者
蓝少枢
LAN Shao-shu. Zengcheng Yongning(Street Phoenix Community Health Service Center, Guangzhou 511340, China)
出处
《中国实用医药》
2017年第28期105-107,共3页
China Practical Medicine
关键词
喘息性支气管炎
小儿
孟鲁司特钠
Asthmatic bronchitis
Pediatric
Montelukast sodium
